<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00147472</url>
  </required_header>
  <id_info>
    <org_study_id>CTA-Control-088421</org_study_id>
    <nct_id>NCT00147472</nct_id>
  </id_info>
  <brief_title>Positronic Emission Tomography (PET) Imaging in Post Radiation Evaluation of Head and Neck Tumours (PET PREVENT Trial)</brief_title>
  <official_title>A Prospective Cohort Study to Determine the Sensitivity of Positron Emission Tomography (PET) in Detecting Metastatic Cancer in Neck Lymph Nodes in Patients With Squamous Cell Head &amp; Neck Cancer Managed With Primary Radiation Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ontario Clinical Oncology Group (OCOG)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ontario Ministry of Health and Long Term Care</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ontario Clinical Oncology Group (OCOG)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to determine the ability of positron emission tomography (PET)&#xD;
      to detect residual cancer in neck lymph nodes of patients following curative treatment with&#xD;
      radiation therapy for squamous cell cancer arising in the head and neck.&#xD;
&#xD;
      Patients with head and neck cancer (HNC) undergo treatment of curative intent; patients who&#xD;
      are node positive (N2 N3 stages) undergo standard management which includes post-radiation&#xD;
      planned neck dissection but two thirds of patients end up not having evidence of residual&#xD;
      disease in neck dissection specimens; these patients could have avoided surgery. However,&#xD;
      currently used standard tests, like computed tomography (CT) and/or magnetic resonance&#xD;
      imaging (MRI) cannot reliably predict who is post-radiation disease free.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PET-Fluorodeoxyglucose scanning is an imaging test based on the increased uptake of&#xD;
      radiolabelled glucose by tumour cells. PET might detect neck tumours better than other&#xD;
      imaging tests. This is a cohort study in which patients with N2 N3 squamous cell carcinoma of&#xD;
      the head and neck undergo a PET and a CT scan at baseline and then post-radiation therapy and&#xD;
      chemotherapy. Then, they undergo neck dissection surgery. The PET and CT results are compared&#xD;
      with the presence or absence of tumours in the neck nodes. If PET is sufficiently accurate in&#xD;
      predicting the presence or absence of tumours in the neck nodes, then a neck dissection could&#xD;
      be avoided.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2004</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ability of PET compared to CT in identifying the presence of tumour in neck nodes</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumour at the primary site 8-10 weeks following radiation;</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in PET signal (standard uptake value;</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local recurrence, distant metastases and survival</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">400</enrollment>
  <condition>Cancer of the Head and Neck</condition>
  <arm_group>
    <arm_group_label>PET</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>All patients receive PET scan and conventional CT imaging.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>PET scan in addition to conventional CT imaging</intervention_name>
    <description>PET scans, Pre and post radiation treatment</description>
    <arm_group_label>PET</arm_group_label>
    <other_name>FDG PET</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        All of the following criteria must be satisfied:&#xD;
&#xD;
          1. Histological evidence of squamous cell carcinoma of the head &amp; neck (T1-T4 arising in&#xD;
             either the oral cavity, larynx &amp; pharynx, except Nasopharyngeal carcinoma);OR patients&#xD;
             with histological evidence of squamous cell carcinoma metastatic to the neck and an&#xD;
             unknown primary site after conventional workup without any of the following: i).&#xD;
             Clinically suspected skin primary or previous diagnosis of skin cancer arising in the&#xD;
             head and neck area; ii). Patients of Asian or African decent -possible nasopharynx&#xD;
             primary; iii). Patients whose malignant adenopathy is confined to zone V -possible&#xD;
             nasopharynx primary; and iv). Patients whose malignant adenopathy is confined to zone&#xD;
             IV (supraclavicular)-possible lung primary.&#xD;
&#xD;
          2. Presence of advanced N2 or N3 neck disease.&#xD;
&#xD;
          3. Planned for primary curative radiation therapy (Â± chemotherapy) followed by neck&#xD;
             dissection eight to twelve weeks after completion of treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Presence of distant metastasis&#xD;
&#xD;
          2. Recurrent tumour&#xD;
&#xD;
          3. Prior neo-adjuvant chemotherapy&#xD;
&#xD;
          4. Previous radiation therapy to intended treatment volumes&#xD;
&#xD;
          5. Other active malignancy&#xD;
&#xD;
          6. Surgically inoperable neck disease&#xD;
&#xD;
          7. Unable to remain supine for 60 minutes&#xD;
&#xD;
          8. Unfit to undergo general anesthetic or neck dissection for medical reasons&#xD;
&#xD;
          9. Known hypersensitivity to CT contrast&#xD;
&#xD;
         10. Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Waldron, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Princess Margaret Hospital, Canada</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ralph Gilbert, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Princess Margaret Hospital, Canada</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Libni Eapen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ottawa Regional Cancer Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anne Keller, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Princess Margaret Hospital, Canada</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mark N Levine, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ontario Clinical Oncology Group (OCOG)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bayardo Perez-Ordonez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Princess Margaret Hospital, Canada</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chu-Shu Gu, M.Sc.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ontario Clinical Oncology Group (OCOG)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Juravinski Cancer Centre</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London Regional Cancer Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ottawa Regional Cancer Centre</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 1C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <study_first_submitted>September 1, 2005</study_first_submitted>
  <study_first_submitted_qc>September 6, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 7, 2005</study_first_posted>
  <last_update_submitted>June 20, 2012</last_update_submitted>
  <last_update_submitted_qc>June 20, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 22, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Head and neck</keyword>
  <keyword>Cancer</keyword>
  <keyword>Diagnosis</keyword>
  <keyword>Fluorodeoxyglucose</keyword>
  <keyword>Positron-Emission Tomography</keyword>
  <keyword>PET</keyword>
  <keyword>Oncology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

